Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingBlue Cross Blue Shield - Kansas FDG‑PET Coverage U…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedBlue Cross Blue Shield - KansasPolicy N/A

    PET Scanning- Oncologic Applications (Lung)

    Customize your policy alerts

    Sign up for all blue cross blue shield - kansas policy alerts

    Know when blue cross blue shield - kansas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and clinical-policy framework for use of 18F-FDG PET and FDG-PET/CT in diagnosis, staging, restaging, and surveillance of lung cancer for Blue Cross and Blue Shield of Kansas members.

    Policy Summary
    PayerBlue Cross Blue Shield - Kansas
    PolicyPET Scanning- Oncologic Applications (Lung)
    Policy CodePolicy N/A
    Change TypeMaterial revisions — new lung‑specific policyterminology clarified to FDG‑PET or FDG‑PET/CT
    Effective DateN/A
    Last ReviewSep 25, 2025
    Next Review DateN/A
    Key ActionVerify member benefits and prior authorization requirements with BCBSKS before scheduling PET/PET‑CT.
    SourceLink
    POLICY UPDATE CHANGES

    Oncologic Applications for Lung has been split out into a separate medical policy, Positron Emission Tomography (PET) Scanning: Oncologic Applications (Lung).

    Policy language updated to specify FDG-PET or FDG-PET/CT terminology replacing generic 'PET' in key policy statements.

    Clarified definitions for Diagnosis, Staging, Restaging, and Surveillance within the policy guidelines.

    Language suggesting PET be considered only after other imaging techniques or as a retrospective review was removed.

    4oncologic PET applications
    Sept 25, 2025most recent literature update
    750SUPE_R trial size
    82% / 81%pooled SPN sensitivity
    Not supportedSCLC surveillance stance

    Coverage Criteria

    Medically Necessary Indications

    FDG-PET or FDG-PET/CT may be considered medically necessary when any of the following apply:

    Medically necessary indications for FDG-PET or FDG-PET/CT in lung cancer: a) Individuals with a solitary pulmonary nodule to distinguish between benign and malignant disease when prior CT scan and chest x-ray findings are inconclusive or discordant; b) As staging or restaging technique in those with known non-small-cell lung cancer; c) To determine resectability for individuals with a presumed solitary metastatic lesion from lung cancer; d) Staging of small-cell lung cancer if limited stage is suspected based on standard imaging.

    Source: policy statements (A. Lung Cancer, items 1-2).

    Experimental / Investigational

    FDG-PET or FDG-PET/CT is considered experimental / investigational for:

    Experimental/investigational indications: Staging of small-cell lung cancer when extensive stage is already established and in all other aspects of managing small-cell lung cancer not specified as medically necessary.

    Source: policy statements (A. Lung Cancer, item 3).

    Policy Summary
    PayerBlue Cross Blue Shield - Kansas
    PolicyPET Scanning- Oncologic Applications (Lung)
    Policy CodePolicy N/A
    Change TypeMaterial revisions — new lung‑specific policyterminology clarified to FDG‑PET or FDG‑PET/CT
    Effective DateN/A
    Last ReviewSep 25, 2025
    Next Review DateN/A
    Key ActionVerify member benefits and prior authorization requirements with BCBSKS before scheduling PET/PET‑CT.
    SourceLink
    On This Page
    Coverage CriteriaCovered Indications (Diagnosis, Staging, Restaging)Not Covered / Not Medically NecessaryCoding and BillingProvider Actions and AuthorizationDefinitionsContrast and Modality RulesPrior AuthorizationBackgroundRevision History

    Covered Indications

    Covered when indications align with guideline-supported uses:

    Staging/diagnosis of lung cancer: Skull base to mid-thigh FDG-PET/CT is recommended for initial clinical staging to evaluate for extrathoracic metastases and is covered for individuals with suspected or confirmed NSCLC or SCLC when used to guide curative-intent therapy or to clarify stage.

    Supported by ACR and NCCN guidance (ACR 2019/2025; NCCN v.8.2025 for NSCLC, v.2.2026 for SCLC).

    Solitary pulmonary nodule evaluation: FDG-PET may be used for evaluation of solitary pulmonary nodules when diagnosis remains uncertain after CT or chest radiograph; in low-pretest-probability individuals a negative PET may support avoidance of invasive biopsy.

    Meta-analyses and clinical guidance support use in this scenario.

    Restaging and suspected recurrence: FDG-PET/CT is covered to evaluate suspected recurrence or progression following therapy when clinical or imaging findings raise concern; biopsy confirmation is required prior to initiating additional treatment if PET/CT suggests recurrence within areas recently treated with radiation.

    ACR and NCCN cite PET/CT as usually appropriate for posttreatment evaluation when recurrence is suspected; biopsy confirmation advised because FDG avidity may persist up to 2 years after radiation.

    SCLC staging when limited stage suspected: FDG-PET/CT is covered for initial staging in suspected limited-stage SCLC when curative treatment is being considered or when PET/CT is needed to clarify stage; if extensive-stage SCLC is already established, MRI brain or contrast CT is preferred for further assessment.

    Guideline-supported though evidence quality is low.

    Not Medically Necessary / Not Covered

    Not covered / not supported by evidence:

    Routine surveillance after definitive therapy: Routine skull base to mid-thigh FDG-PET/CT for surveillance after definitive therapy in stage I-III NSCLC or SCLC in asymptomatic patients (without clinical or imaging suspicion) is not supported by the evidence and is not covered; randomized trial data showed no improvement in curative treatment rates, recurrence-free survival, or overall survival and demonstrated increased invasive diagnostic procedures with PET surveillance.

    SUPE_R randomized trial (n=750) and section summaries for NSCLC and SCLC indicate lack of benefit for routine surveillance.

    Small Cell Lung Cancer

    Covered when criteria below are met for oncologic application:

    SCLC diagnosis/staging/restaging: FDG-PET and FDG-PET/CT are supported for diagnosis, staging, and restaging of small-cell lung cancer, particularly when limited stage is suspected or to clarify staging prior to curative-intent therapy.

    Systematic reviews, meta-analyses, and guideline statements support use for these indications though study quality is low.

    SCLC surveillance not supported: Routine surveillance FDG-PET or FDG-PET/CT for small-cell lung cancer is not supported by the evidence and is not covered.

    Policy section summary and national coverage entries indicate surveillance for SCLC is not supported.

    National Coverage Summary

    National FDG PET coverage summary indicates:

    National coverage entries: National coverage table lists initial treatment strategy (diagnosis & staging) and subsequent treatment strategy (restaging & monitoring response to treatment) as 'Cover' for small cell lung and for non-small-cell lung in the respective categories; specific tumor-type exceptions are noted elsewhere in the table.

    See national coverage table entries within the policy document.

    FDG-PET and FDG-PET/CT have a defined role in staging small-cell lung cancer (SCLC) when the clinical or standard imaging assessment suggests limited-stage disease and results will influence curative-intent management. Conversely, when extensive-stage SCLC is already established by other imaging or clinical evaluation, FDG-PET/FDG-PET/CT is considered experimental/investigational for additional staging because it is unlikely to change overall management; in that situation, MRI or contrast-enhanced CT are preferred for further assessment. These distinctions reflect guideline-supported uses for clarifying stage when limited disease is suspected and the lower-quality evidence for additional PET utility once extensive disease is known.

    Routine use of FDG-PET or FDG-PET/CT for surveillance after completion of definitive therapy in asymptomatic patients with non–small-cell lung cancer (NSCLC) is not supported. A large randomized trial (SUPE_R, n=750) comparing scheduled PET/CT surveillance to contrast-enhanced CT found that PET/CT detected more suspected recurrences but did not improve time to recurrence, rates of curative-intent treatment, recurrence-free survival, or overall survival and resulted in more invasive diagnostic procedures. Therefore, PET/CT is recommended for evaluation when there is specific clinical or imaging suspicion of recurrence rather than as routine surveillance.

    Current evidence does not support the use of FDG-PET or FDG-PET/CT for routine surveillance of small-cell lung cancer (SCLC). Systematic reviews and meta-analyses indicate PET/CT may be useful for diagnosis, staging, and restaging of SCLC, but the evidence does not demonstrate benefit for surveillance imaging in asymptomatic patients.

    FDG-PET or FDG-PET/CT is considered experimental/investigational for staging of SCLC when extensive-stage disease is already established and for other aspects of SCLC management that are not described as medically necessary in this policy. In established extensive-stage SCLC, additional PET imaging is unlikely to alter treatment decisions, and alternative imaging modalities (MRI or contrast-enhanced CT) are preferred for further evaluation.

    Evidence from randomized and meta-analytic studies indicates that routine surveillance PET/CT for NSCLC does not improve meaningful clinical outcomes. In the SUPE_R randomized trial (n=750), PET/CT surveillance detected more suspected recurrences but did not increase the proportion of recurrences treated with curative intent (48% in both arms), nor did it improve time to recurrence or overall survival, and it led to a higher rate of invasive diagnostic procedures. Meta-analyses and guideline summaries similarly conclude that PET/CT is useful for diagnosis, staging, and for evaluation when recurrence is suspected, but not for asymptomatic routine surveillance.

    Based on current systematic reviews and meta-analyses, routine surveillance FDG-PET or FDG-PET/CT for small-cell lung cancer (SCLC) is considered not medically necessary. Although PET/CT may aid in staging and restaging—particularly when limited-stage disease is suspected—the available evidence does not support its use for routine monitoring in asymptomatic patients.

    Covered Indications (Diagnosis, Staging, Restaging)

    FDG-PET or FDG-PET/CT for lung cancer diagnosis, staging, restaging

    FDG-PET or FDG-PET/CT for lung cancer diagnosis, staging, restaging: FDG-PET or FDG-PET/CT may be used for diagnosis (to help establish presence of malignancy), staging (to determine extent at diagnosis, often to evaluate for extrathoracic metastases), and restaging (to evaluate suspected recurrence or to determine extent after completion of treatment).

    Definitions and policy statements (Policy Guidelines and A. Lung Cancer).

    Appropriate use recommendations

    Initial staging recommendation: Skull base to mid-thigh FDG-PET/CT is recommended for initial clinical staging to evaluate for extrathoracic metastases in individuals with NSCLC and is usually appropriate per ACR; NCCN indicates PET/CT can be used for staging, detection of metastases, and treatment planning.

    ACR 2019/2025 and NCCN guidance (NSCLC).

    Posttreatment evaluation when recurrence suspected: Skull base to mid-thigh FDG-PET/CT is usually appropriate for posttreatment evaluation of stage I-III NSCLC and may be appropriate for posttreatment evaluation of SCLC when clinical suspicion for recurrence or progression exists; PET/CT is not recommended for routine surveillance without clinical indication.

    ACR 2025 surveillance criteria and NCCN SCLC guidance; biopsy confirmation required if PET suggests recurrence within previously irradiated areas.

    Lung cancer (SCLC and NSCLC) — diagnosis, staging, restaging

    Diagnosis, staging, restaging for SCLC and NSCLC: FDG-PET or FDG-PET/CT may be used for diagnosis, staging (including when limited stage is suspected), and restaging (when recurrence is suspected or to determine extent after treatment) for both SCLC and NSCLC, aligned with guideline recommendations; PET is not recommended for brain metastasis detection—MRI preferred.

    Policy summaries and coding/definitions (Section summaries; Coding revisions).

    Not Covered / Not Medically Necessary

    Staging with FDG-PET or FDG-PET/CT is not covered when extensive-stage SCLC has already been established and when additional PET imaging would not alter other aspects of management. In such cases PET/CT is considered experimental/investigational and alternative imaging modalities (MRI or contrast CT) are preferred for further assessment.

    Routine PET/CT as surveillance imaging after definitive therapy for NSCLC or SCLC in asymptomatic patients without specific clinical or imaging suspicion is not covered. High-quality evidence, including a large randomized trial, found no survival or curative-treatment benefit from scheduled PET/CT surveillance and documented increased downstream invasive procedures.

    FDG-PET and FDG-PET/CT for routine surveillance of small-cell lung cancer in asymptomatic patients are not supported by the evidence and are therefore not covered. While PET/CT may be appropriate for diagnosis, staging, or restaging when clinical suspicion exists, its routine use for surveillance lacks demonstrated benefit.

    Coding and Billing

    Radiotracermixed
    18F-FDGFluorine 18 fluorodeoxyglucose radiotracer (regulatory status; common oncologic tracer)
    Listed PET procedure and radiopharmaceutical codesCPT | HCPCS | mixed
    78608Brain imaging, positron emission tomography (PET); metabolic evaluation.
    78609Brain imaging, positron emission tomography (PET); perfusion evaluation.
    78811Positron emission tomography (PET) imaging; limited area (e.g. Chest, head/neck).
    78812Positron emission tomography (PET) imaging; skull base to mid-thigh.
    78813Positron emission tomography (PET) imaging; whole body.
    78814Tumor imaging, PET with concurrently acquired CT for attenuation correction and anatomical localization; limited area (e.g. chest, head/neck).
    78815Tumor imaging, PET with concurrently acquired CT for attenuation correction and anatomical localization; skull base to mid-thigh.
    78816Tumor imaging, PET with concurrently acquired CT for attenuation correction and anatomical localization; whole body.
    A9552Fluorodeoxyglucose F-18 FDG, diagnostic, per study dose, up to 45 millicuries.
    A9597Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified.
    1–10 of 12
    1/2
    inv-15: Surveillance timing — timing guidance (≥6 months after treatment; ≥12 months for lymphoma).
    Surveillance intervalImaging in asymptomatic patients performed 6 months or more after completion of treatment (≥12 months for lymphoma)
    Applies toAsymptomatic patients following definitive therapy for cancer
    PurposeDetect recurrent disease in patients without clinical signs or symptoms

    Provider Actions and Authorization

    Prior Authorization

    Verify benefits / Prior Authorization

    Verify member benefits and prior authorization requirements with BCBSKS before ordering PET/CT. Member contract language and state or federal mandates take precedence over this policy and may affect coverage.

    • Verify benefits with Blue Cross and Blue Shield of Kansas Customer Service.
    • Coverage is subject to state/federal mandates and member contract language.
    Prior Authorization

    Prior Authorization for Surveillance PET/CT

    Prior authorization is recommended for routine surveillance or repeated PET/CT studies performed without documented clinical suspicion of recurrence. Routine surveillance PET/CT for NSCLC/SCLC is not supported by the evidence and may be denied.

    • Routine surveillance PET/CT (asymptomatic patients ≥6 months after treatment for solid tumors; ≥12 months for lymphoma) is not supported and may be denied.
    • Prior authorization recommended when PET/CT is requested for surveillance or repeated studies without documented clinical indication.
    Documentation Required

    Biopsy Confirmation After PET/CT–Detected Recurrence

    If PET/CT detects suspected recurrent disease, obtain tissue (biopsy) confirmation prior to initiating additional definitive treatment because FDG avidity can persist after radiation and other therapies.

    • Biopsy confirmation required before starting additional treatment based on PET/CT-detected recurrence.
    • FDG may remain avid in treated areas for up to 2 years; correlate clinically and pathologically.
    Billing Rule

    Coding Informational Note

    The CPT/HCPCS and radiopharmaceutical codes listed in this policy are provided for informational purposes only. Inclusion of a code does not guarantee coverage or reimbursement; services are medically necessary only if performed in accordance with the policy statements and the member's contract.

    • Codes are informational and may not be comprehensive.
    • Code(s) listed are medically necessary ONLY if the procedure is performed according to the Policy section.
    Step Therapy

    Step Therapy Note

    Previous guidance suggesting PET/CT be used only after other imaging modalities has been removed. This policy does not impose a step-therapy sequence requiring CT/MRI prior to PET/CT in all cases; however, clinical documentation should justify the selected imaging modality. Use CT for routine surveillance when supported by evidence and guidelines.

    • Removed language that mandated PET only after other modalities.
    • Clinical documentation should support the chosen imaging strategy (eg, when CT is preferred for routine surveillance).

    Definitions

    inv-29: Staging definition — Use of PET to determine extent of cancer at diagnosis before treatment.
    DefinitionUse of PET to determine the stage (extent) of cancer at the time of diagnosis before any treatment is given (initial staging).
    Typical goalDetermine whether cancer is localized and to guide curative-intent therapy decisions.
    Modality notedFDG-PET or FDG-PET/CT is specified for staging in lung cancer policy statements.
    inv-30: Restaging definition — Imaging after treatment when recurrence is suspected or to determine extent after completion of treatment.
    DefinitionImaging after treatment performed when recurrence is suspected based on signs or symptoms or to determine extent after completion of therapy (restaging).
    When to useWhen clinical or imaging findings raise concern for recurrence or progression; biopsy confirmation recommended if PET suggests recurrence within 2 years of radiation.
    Modality guidanceFDG-PET or FDG-PET/CT supported for restaging in NSCLC and SCLC when recurrence is suspected.
    inv-31: Surveillance definition — Imaging in asymptomatic patients ≥6 months after treatment (≥12 months for lymphoma) to detect recurrent disease.
    DefinitionImaging in asymptomatic patients performed 6 months or more after completion of treatment to detect recurrent disease (≥12 months for lymphoma).
    Evidence stanceNot supported for routine surveillance in NSCLC and SCLC based on available evidence; randomized trial showed no survival benefit for PET/CT surveillance.
    Preferred alternativesSurveillance imaging may preferentially use contrast-enhanced CT rather than PET/CT per trial evidence.
    inv-32: NSCLC definition — Non–small-cell lung cancer context and PET/CT utility.
    TermNSCLC (Non–small-cell lung cancer)
    Clinical roleFDG-PET/CT improves staging (mediastinal lymph node assessment), aids diagnosis, detects metastases, and is supported for staging and restaging.
    Surveillance noteEvidence does not support routine surveillance PET/CT for NSCLC.
    inv-33: SCLC definition — Small-cell lung cancer context and PET/CT utility caveats.
    TermSCLC (Small-cell lung cancer)
    Clinical roleFDG-PET or FDG-PET/CT may aid diagnosis, staging, and restaging, particularly when limited-stage disease is suspected or to clarify staging.
    CaveatIf extensive-stage SCLC is already established, other imaging (MRI or contrast-enhanced CT) is preferred; routine surveillance with PET/CT is not supported by evidence.
    inv-34: Diagnosis definition added to Policy Guidelines.
    Addition'Diagnosis' definition added to Policy Guidelines to define use of PET as part of testing to establish whether a patient has cancer.
    ContextOne of four oncology applications clarified in Policy Guidelines (Diagnosis, Staging, Restaging, Surveillance).
    Effective date notePolicy Guidelines update recorded in coding/revisions history.
    inv-35: Staging definition added to Policy Guidelines.
    Addition'Staging' definition added to Policy Guidelines to specify use of PET to determine cancer extent at diagnosis before treatment (initial staging).
    PurposeClarifies imaging aim is generally to determine whether cancer is localized and may be referred to as initial staging.
    inv-36: Restaging definition added to Policy Guidelines.
    Addition'Restaging' definition added to Policy Guidelines to describe imaging after treatment when recurrence is suspected or to determine extent after completion of treatment (includes both suspected recurrence and post-treatment extent assessment).
    Clinical detailRestaging includes evaluation when signs/symptoms suggest recurrence and assessment after a full course of therapy.
    Policy linkageUsed to support coverage statements for posttreatment evaluation in NSCLC and SCLC.
    inv-37: Surveillance definition added to Policy Guidelines.
    Addition'Surveillance' definition added to Policy Guidelines: imaging in asymptomatic patients ≥6 months after treatment (≥12 months for lymphoma) to detect recurrent disease.
    ImplementationDefines timing threshold for surveillance imaging referenced elsewhere in policy and coding thresholds.
    Coverage impactSupports exclusion of routine PET/CT surveillance for NSCLC and SCLC per evidence statements.

    Contrast and Modality Rules

    Billing Rule

    PET tracer and radiation considerations

    PET commonly uses the 18F-FDG tracer and PET/CT combines metabolic and anatomic data; radiation exposure from PET and PET/CT is considered moderate to high and should be considered when ordering imaging.

    • 18F-FDG is the most common tracer for oncologic PET imaging.
    • PET/CT provides combined metabolic and anatomic information but involves moderate-to-high radiation exposure.
    Billing Rule

    MRI preferred for brain metastasis detection

    PET is not recommended for detection of brain metastases from lung cancers; MRI is the preferred imaging modality for brain metastasis evaluation.

    • NCCN notes PET is not recommended for detection of brain metastasis from lung cancers; use MRI for brain imaging.
    • Meta-analysis comparing MRI and FDG-PET for brain metastases supports MRI preference.
    Billing Rule

    Prefer MRI or contrast CT when extensive-stage SCLC is established

    If extensive-stage small-cell lung cancer is already established, MRI or contrast-enhanced CT is preferred for further staging evaluation rather than PET/CT.

    • Guidelines support PET/CT when limited-stage SCLC is suspected, but prefer MRI or contrast CT if extensive-stage disease is established.
    • Use alternative imaging modalities for staging when extensive-stage SCLC is present.

    Prior Authorization

    Prior Authorization

    Verify benefits and prior authorization with BCBSKS

    Verify member benefits and prior authorization requirements with BCBSKS before ordering PET or PET/CT; member contract language takes precedence for coverage determinations.

    • Prior authorization requirements are determined by the member's contract and payer rules.
    • Contact BCBSKS Customer Service to confirm coverage and any required authorizations.
    Prior Authorization

    Prior authorization recommended for surveillance PET/CT

    Prior authorization is recommended for PET/CT when used for routine surveillance or for repeated studies without documented clinical suspicion, per policy guidance.

    • PET/CT is appropriate for initial staging and suspected recurrence but prior authorization may be needed for surveillance uses.
    • Document clinical suspicion to support medical necessity for surveillance imaging.
    Billing Rule

    Use listed codes in prior authorization workflows as applicable

    The codes provided in the policy (procedure and radiopharmaceutical codes) may be used in authorization workflows per payer rules; confirm code use with BCBSKS during authorization.

    • Codes such as 78812, 78815, A9552, and G0235 are listed for informational/authorization purposes.
    • Confirm applicable codes and billing rules with the payer during prior authorization.

    Background

    Positron emission tomography (PET) is a nuclear medicine imaging technique that uses positron-emitting radiotracers—most commonly 18F‑FDG (fluorine 18 fluorodeoxyglucose)—to image tissue metabolic activity. PET provides functional information about glucose metabolism and, when combined with CT as FDG-PET/CT, pairs metabolic data with anatomic localization. Depending on the clinical question, PET can help distinguish benign from malignant lesions, detect regional nodal disease and distant metastases, and aid in staging, restaging, and treatment planning. Radiation exposure is moderate to high and tracer selection varies by tumor type and indication.

    Revision History

    2026-01-27policy_revisionLatest

    Policy language updated to specify FDG-PET or FDG-PET/CT replacing generic 'PET' in key policy statements and added A1: FDG-PET or FDG-PET/CT; A1 PET wording removed; A1a removed; A2/A3 changed from PET to FDG-PET or FDG-PET/CT.

    2025-01-28policy_split

    Oncologic Applications for Lung was split out from a broader Positron Emission Tomography (PET) Scanning: Oncologic Applications medical policy into a separate lung-specific policy.